Newer antiobesity medications change the body s defended fat mass (set point) to something more normal, rather than "fixing" it at a lower target, which is a good thing, says a clinician.
Prescriptions for Wegovy rose sixfold between December 2022 and June 2023 while those for Ozempic jumped 65%, with general and family practice providers writing the majority of prescriptions.
With nutrient-stimulated hormone therapies for obesity in phase 3 trials, and activin-receptor inhibitors the next upcoming drug class, highly effective treatments for obesity are in sight.